Bausch Health Companies Inc. (BHC)

Market Cap	2.61B
Revenue (ttm)	8.97B
Net Income (ttm)	-455.00M
Shares Out	366.80M
EPS (ttm)	-1.23
PE Ratio	n/a
Forward PE	1.74
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,251,654
Open	7.21
Previous Close	7.13
Day's Range	7.09 - 7.30
52-Week Range	5.86 - 11.46
Beta	0.90
Analysts	Buy
Price Target	13.50 (+89.61%)
Earnings Date	May 2, 2024

About BHC

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Thomas J. Appio
• Employees: 20,270
• Stock Exchange: NYSE
• Ticker Symbol: BHC

Financial Performance

In 2023, BHC's revenue was $8.76 billion, an increase of 7.79% compared to the previous year's $8.12 billion. Losses were -$592.00 million, 163.1% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for BHC stock is "Buy." The 12-month stock price forecast is $13.5, which is an increase of 89.61% from the latest price.

Price Target

$13.5

(89.61% upside)

Analyst Consensus: Buy